Letters from the Lab – Preprint Resveratrol Antiviral Studies

Letters from the Lab

What is Letters from the Lab?

Through this new series we will be sharing research information from Hospitals and Universities around the world. The format will be unfiltered with zero marketing influence, just the data for all us science nerds.

We have some early news regarding the initial findings of two independent studies showing the potential benefits of resveratrol & copper and resveratrol & pterostilbene as related to SARS-CoV-2. We are pleased that Transmax resveratrol was the selected resveratrol used in the Resveratrol and Copper study.

The results of these studies are very positive however please note this is only a first evaluation. The anti-viral properties of resveratrol and other polyphenols are well known and could be effective in the prevention and/or treatment of influenza virus, respiratory syncytial virus and SARS-CoV-2.(2) This combined with the positive results resveratrol had on the inhibition of MERS-CoV virus gives us great excitement to the potential of these compounds and virus treatment options.(1)

1 Lin, S., Ho, C., Chuo, W. et al. Effective inhibition of MERS-CoV infection by resveratrol. BMC Infect Dis 17, 144 (2017) https://doi.org/10.1186/s12879-017-2253-8 2 Therapeutic potential of resveratrol against emerging respiratory viral infections; https://doi.org/10.1016/j.pharmthera.2020.107613

Notice: These are preliminary reports that have not been peer-reviewed. These reports should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information.

Resveratrol and Pterostilbene Potently Inhibit SARS-CoV-2 Infection In Vitro

doi: https://doi.org/10.1101/2020.09.24.285940


The current COVID-19 pandemic is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and has an enormous impact on human health and economy1. In search for therapeutic options, researchers have proposed resveratrol, a food supplement with known antiviral, anti-inflammatory and antioxidant properties as an advantageous antiviral therapy for SARS-CoV-2 infection2–4. Here, we provide evidence that both resveratrol and its metabolically more stable structural analog, pterostilbene, exhibits potent antiviral properties against SARS-CoV-2 in vitro.

Resveratrol and pterostilbene showed antiviral activity in African green monkey kidney cells and in human primary bronchial epithelial cells cultured in an air-liquid interface system. Mechanistic analyses demonstrated that both compounds actively interfere with the post-entry steps of virus replication cycle and their antiviral activity is long-lasting. Collectively, our data indicate that resveratrol and pterostilbene are promising antiviral compounds to treat SARS-CoV-2 infection and advocate evaluation of these compounds in clinical trials.

1 John Hopkins university and medicine. https://coronavirus.jhu.edu/map.html.
2 Marinella, M. A. Indomethacin and resveratrol as potential treatment adjuncts for SARS-CoV-2/COVID-19. Int. J. Clin. Pract. (2020) doi:10.1111/ijcp.13535.
3 van der Voort, P. H. et al. Leptin levels in SARS-CoV-2 infection related respiratory failure: a cross-sectional study and a pathophysiological framework on the role of fat tissue. Heliyon (2020) doi:10.1016/j.heliyon.2020.e04696.
4 Horne, J. R. & Vohl, M. C. Biological plausibility for interactions between dietary fat, resveratrol, ACE2, and SARS-CoV illness severity. American Journal of Physiology – Endocrinology and Metabolism (2020) doi:10.1152/AJPENDO.00150.2020.

Resveratrol and Copper for treatment of severe COVID-19: an observational study (RESCU 002)



To be universally applicable in treatment of severe COVID-19, novel therapies, especially those with little toxicity and low cost, are urgently needed. We report here the use of one such therapeutic combination involving two commonly used nutraceuticals, namely resveratrol and copper in patients with this disease. This study was prompted by pre-clinical reports that sepsis-related cytokine storm and fatality in mice can be prevented by oral administration of small quantities of resveratrol and copper. Since cytokine storm and sepsis are major causes of death in severe COVID-19, we retrospectively analyzed outcomes of patients with this condition who had received resveratrol and copper.

We provide preliminary results of a novel approach to the treatment of severe COVID-19 using a combination of small amounts of commonly used nutraceuticals, which is non-toxic and inexpensive, and therefore could be widely accessible globally. The nearly two-fold reduction in mortality with resveratrol-copper observed in our study needs to be confirmed in a randomized controlled trial.

Notice: These are preliminary reports that have not been peer-reviewed. These reports should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information.


Leave a reply